Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
37
TRDA Quote, Financials, Valuation and Earnings
Last price:
$17.60
Seasonality move
:
-24.47%
Day range:
$16.86 - $18.00
52-week range:
$11.35 - $21.79
Dividend yield:
0%
P/E ratio:
11.07x
P/S ratio:
2.95x
P/B ratio:
1.56x
Volume:
357.3K
Avg. volume:
134.3K
1-year change:
17.41%
Market cap:
$658.6M
Revenue:
$129M
EPS (TTM):
$1.59
Analysts' Opinion
-
Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Entrada Therapeutics has an estimated upside of 50.16% from its current price of $17.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $17.60.
Fair Value
-
According to the consensus of 0 analysts, Entrada Therapeutics has 50.16% upside to fair value with a price target of -- per share.
TRDA vs. S&P 500
-
Over the past 5 trading days, Entrada Therapeutics has overperformed the S&P 500 by 1.68% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Entrada Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Entrada Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Entrada Therapeutics reported revenues of $19.6M.
Earnings Growth
-
Entrada Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Entrada Therapeutics reported earnings per share of -$0.35.
Enterprise value:
209.2M
EV / Invested capital:
0.50x
Price / LTM sales:
2.95x
EV / EBIT:
3.62x
EV / Revenue:
0.97x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-11.98x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
3.41x
Gross Profit (TTM):
--
Return On Assets:
10.56%
Net Income Margin (TTM):
25.53%
Return On Equity:
17.06%
Return On Invested Capital:
17.06%
Operating Margin:
-110.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $215.2M | $43.7M | $19.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$90.1M | -$33.6M | $57.8M | $14M | -$21.7M | |
| EBITDA | -$88.4M | -$31M | $61.3M | $14.8M | -$20.7M | |
| Diluted EPS | -$3.12 | -$0.76 | $1.59 | $1.02 | -$0.35 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $123.5M | $234.7M | $383M | $465.3M | |
| Total Assets | -- | $132.4M | $274.5M | $485M | $554.6M | |
| Current Liabilities | -- | $7.2M | $21.6M | $165.4M | $70.6M | |
| Total Liabilities | -- | $205M | $41.2M | $238.4M | $132.1M | |
| Total Equity | -- | -$72.6M | $233.2M | $246.7M | $422.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$87M | $116.5M | -$14M | -$24.5M | -$24.3M | |
| Cash From Investing | -$168.8M | -$138.6M | -$62.1M | -$3.7M | -$82.9M | |
| Cash From Financing | $190.9M | $20.7M | $102.3M | $368K | -$11K | |
| Free Cash Flow | -$90.5M | $111.2M | -$17.5M | -$25.9M | -$24.9M | |
TRDA
Sector
Market Cap
$658.6M
$44.6M
Price % of 52-Week High
80.77%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
17.41%
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$18.02
200-day SMA
Buy
Level
$15.77
Bollinger Bands (100)
Buy
Level
15.2 - 18.88
Chaikin Money Flow
Sell
Level
-764.8K
20-day SMA
Sell
Level
$19.27
Relative Strength Index (RSI14)
Sell
Level
41.98
ADX Line
Buy
Level
9.65
Williams %R
Buy
Level
-84.9899
50-day SMA
Sell
Level
$18.48
MACD (12, 26)
Sell
Level
-0.27
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
4.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.5452)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Stock Forecast FAQ
In the current month, TRDA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TRDA average analyst price target in the past 3 months is --.
-
Where Will Entrada Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Entrada Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Entrada Therapeutics?
Analysts are divided on their view about Entrada Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Entrada Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Entrada Therapeutics's Price Target?
The price target for Entrada Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TRDA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Entrada Therapeutics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TRDA?
You can purchase shares of Entrada Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Entrada Therapeutics shares.
-
What Is The Entrada Therapeutics Share Price Today?
Entrada Therapeutics was last trading at $17.60 per share. This represents the most recent stock quote for Entrada Therapeutics. Yesterday, Entrada Therapeutics closed at $17.60 per share.
-
How To Buy Entrada Therapeutics Stock Online?
In order to purchase Entrada Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
